FGF23 and chronic kidney disease: Additionally, interleukin-1β induction has been linked to increased FGF23, and the use of a neutralizing antibody to interleukin-1β effectively blocked FGF23 expression in both congenital CKD models and nephrotoxic serum-mediated models.